OTC •
Healthcare •
Biotechnology •
Quote as of 05/29/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization51,464 mln
Float120 mln
Earnings Date07/30/2026
EPS
9.33
Stretched
P / E
31.07
Overvalued
Piotroski F-Score
9
/ 9
Exceptional
Beneish M-Score
-2.49
Borderline
Relative Strength
55
/ 100
Slightly ahead
Debt / Equity
0.21
Very low leverage
Business Description
UCB is a Belgium-based medical company founded in 1925 that focuses on developing treatments for people living with neurological and immune system conditions. Its portfolio includes medicines for epilepsy, Parkinson's disease, rheumatoid arthritis, psoriasis, osteoporosis, and several rare disorders, among others. The company also has a number of new treatments in development targeting conditions such as Alzheimer's disease, lupus, and chronic lung disease, while additionally providing contract manufacturing services to other organizations.
